A Randomized Phase II Trial of First-Line Metastatic Breast Cancer (MBC) Patients: Sub-Set Analysis of Albumin-Bound Paclitaxel (ab-pac) Given Weekly at 150 mg/m2.

被引：0
|
作者：
Gradishar, W. J. [1 ]
Krasnojon, D. [1 ]
Cheporov, S. [1 ]
Makhson, A. N. [1 ]
Manikhas, G. M. [1 ]
Clawson, A. [1 ]
Bhar, P. [1 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-13
引用
收藏
页数：2
相关论文
共 50 条
  • [21] CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)
    Martin, M.
    Hurvitz, S.
    Kennedy, J.
    Forbes, J.
    Roche, H.
    Pinter, T.
    Eiermann, W.
    Buyse, M.
    Rupin, M.
    Mackey, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 260 - 260
  • [22] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Gasparini, Giampietro
    Gion, Massimo
    Mariani, Luigi
    Papaldo, Paola
    Crivellari, Diana
    Filippelli, Gianfranco
    Morabito, Alessandro
    Silingardi, Vittorio
    Torino, Francesco
    Spada, Antonella
    Zancan, Matelda
    De Sio, Livia
    Caputo, Antonio
    Cognetti, Francesco
    Lambiase, Antonio
    Amadori, Dino
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 101 (03) : 355 - 365
  • [23] Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer
    Giampietro Gasparini
    Massimo Gion
    Luigi Mariani
    Paola Papaldo
    Diana Crivellari
    Gianfranco Filippelli
    Alessandro Morabito
    Vittorio Silingardi
    Francesco Torino
    Antonella Spada
    Matelda Zancan
    Livia De Sio
    Antonio Caputo
    Francesco Cognetti
    Antonio Lambiase
    Dino Amadori
    Breast Cancer Research and Treatment, 2007, 101 : 355 - 365
  • [24] Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
    Reynolds, Craig
    Barrera, David
    Jotte, Robert
    Spira, Alexander I.
    Weissman, Charles
    Boehm, Kristi A.
    Pritchard, Sharon
    Asmar, Lina
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (12) : 1537 - 1543
  • [25] Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) plus capecitabine (XEL) in first line treatment of metastatic breast cancer (MBQ): interim results.
    Schwartzberg, L. S.
    Arena, F.
    Mintzer, D.
    Epperson, A.
    Fu, D.
    Fortner, B., V
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S70 - S70
  • [26] Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer
    Jahanzeb, M
    Mortimer, JE
    Yunus, F
    Irwin, DH
    Speyer, J
    Koletsky, AJ
    Klein, P
    Sabir, T
    Kronish, L
    ONCOLOGIST, 2002, 7 (05): : 410 - 417
  • [27] Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial*
    Adkins, Douglas
    Ley, Jessica
    Atiq, Omar
    Powell, Steven
    Spanos, William C.
    Gitau, Mark
    Rigden, Caron
    Palka, Kevin
    Liu, Jingxia
    Oppelt, Peter
    ORAL ONCOLOGY, 2021, 115
  • [28] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/NEU positive metastatic breast cancer (MBC):: final results of a multicenter randomized phase IIb trial
    Gasparini, G
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S94 - S94
  • [30] Phase II Study Evaluating Lapatinib (L) in Combination with Albumin Bound Paclitaxel (ab-Pac) in Women Who Have Received 0-1 Chemotherapy Regimen for HER2 Overexpressing (HER2+) Metastatic Breast Cancer (MBC)
    Yardley, D. A.
    Hart, L.
    Bosserman, L.
    Saleh, M. N.
    Waterhouse, D. M.
    Richards, P.
    Hagan, M. K.
    DeSilvio, M. L.
    Mahoney, J. M.
    Nagarwala, Y.
    CANCER RESEARCH, 2011, 71
12345